Zacks Research Has Bearish Estimate for Amgen Q3 Earnings

Amgen Inc. (NASDAQ:AMGN) – Equities research analysts at Zacks Research lowered their Q3 2025 earnings estimates for Amgen in a report released on Wednesday, December 4th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $5.21 for the quarter, down from their previous estimate of $5.22. The consensus estimate for Amgen’s current full-year earnings is $19.51 per share. Zacks Research also issued estimates for Amgen’s Q3 2026 earnings at $5.42 EPS.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter last year, the company earned $4.96 earnings per share. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis.

A number of other analysts also recently weighed in on AMGN. StockNews.com downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 28th. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. William Blair reissued an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. TD Cowen raised their price target on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, Sanford C. Bernstein began coverage on shares of Amgen in a research report on Thursday, October 17th. They set an “outperform” rating and a $380.00 price target for the company. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus price target of $323.05.

Amgen Stock Up 1.9 %

AMGN stock opened at $277.63 on Monday. Amgen has a twelve month low of $257.80 and a twelve month high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The company has a market capitalization of $149.23 billion, a P/E ratio of 35.55, a PEG ratio of 3.02 and a beta of 0.55. The firm has a 50 day simple moving average of $305.69 and a 200-day simple moving average of $315.66.

Hedge Funds Weigh In On Amgen

A number of institutional investors have recently bought and sold shares of the stock. State Street Corp increased its stake in Amgen by 1.2% in the 3rd quarter. State Street Corp now owns 29,317,018 shares of the medical research company’s stock worth $9,446,236,000 after purchasing an additional 345,537 shares in the last quarter. Geode Capital Management LLC grew its stake in Amgen by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 12,122,889 shares of the medical research company’s stock valued at $3,893,771,000 after acquiring an additional 103,851 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Amgen by 2.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 10,532,629 shares of the medical research company’s stock valued at $3,393,718,000 after acquiring an additional 251,876 shares in the last quarter. Janus Henderson Group PLC grew its stake in Amgen by 11.7% during the 3rd quarter. Janus Henderson Group PLC now owns 5,143,330 shares of the medical research company’s stock valued at $1,657,183,000 after acquiring an additional 538,545 shares in the last quarter. Finally, Pathway Financial Advisers LLC grew its stake in Amgen by 33,125.4% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company’s stock valued at $1,437,115,000 after acquiring an additional 4,446,757 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 9th. Investors of record on Monday, November 18th were paid a $2.25 dividend. The ex-dividend date of this dividend was Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a yield of 3.24%. Amgen’s dividend payout ratio is currently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.